Article Text

other Versions

PDF
Review
Depression in glioma: a primer for clinicians and researchers
  1. Alasdair G Rooney1,
  2. Paul D Brown2,
  3. Jacob C Reijneveld3,
  4. Robin Grant1
  1. 1Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland, UK
  2. 2MD Anderson Cancer Centre, Houston, USA
  3. 3Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
  1. Correspondence to Dr Alasdair G Rooney, Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh Scotland EH4 2XU, UK; a.rooney{at}nhs.net

Abstract

Depression is one of the leading causes of global disability, and a considerable hidden morbidity among patients with glioma. In this narrative review, we summarise what is currently known about depression in glioma, the main unanswered questions and the types of studies that should be prioritised in order to find out. We conclude by calling for a prospective Phase II study of antidepressants in depressed glioma patients, to test methodologies for a multicentre randomised controlled trial.

  • Depression

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.